Marketing to Professionals: Detailing
For sales reps to believe in the value of the detail piece, they need to see evidence that it's working. Currently, neither marketing nor sales tests the detail piece rigorously enough prior to introduction. While the typical brand invests more than $100 million in annual sales-force support, it spends less than $2 million on average to determine whether the detail piece is driving prescriptions. Some companies altogether fail to test the effectiveness of the detail piece during development because of limited budgets or time constraints. (Most pharma companies operate on a pre-determined promotion cycle that only allows for new detail pieces anywhere from two to four times per year.) Instead, companies often will settle for qualitative feedback among the same, small physician panel. This approach not only lacks statistical rigor, but also could lead to biased results that are not representative of the marketplace.
A New Way of Testing
To get an idea of how well the detail piece will perform, companies can do predictive modeling. In order to assess the effectiveness of a detail piece before it gets handed to sales reps, companies can build predictive models that utilize data collected from physician reactions to the tested detail piece. This data can then be analyzed against actual changes in prescribing once the detail piece is submitted to physicians. Historic data is used to create models that benchmark the underlying aspects of a detail piece to give marketers a sense of whether a detail piece will affect prescribing trends.
Tale of Two Pieces
The following case studies highlight the results of two detail pieces for two different brands prior to rollout and the subsequent performance after rollout. These brands (Product X and Product Y) were not direct competitors, though they were in comparably competitive markets with comparable promotion dynamics. Baseline performance trends and market dynamics were judged to be very comparable between the two products, and they targeted the same specialty mix of physicians. Average annual revenue for Product X and Product Y was approximately $1 billion each in the United States. Prior to the launch of the new detail pieces, both products had relatively similar rates of new prescriptions and similar detail quality scores based on tracking of their current sale-force performance in the field.
The following factors were considered:
In separate tests for Product X and Product Y, physicians were exposed to details of the product using the new sales aid. The results of these tests then were analyzed and benchmarked against the other tested pieces. Finally, the results from each test were compared with results captured from tracking ongoing detailing activity for each brand to compare how the new detail might fare against the one currently being used by each sales force. The final analysis of the new detail pieces predicted that Product X's new detail piece would be more effective than its existing detail piece and that it likely would drive an increase in new-prescription market share. Conversely, analysis of Product Y's detail piece predicted that the new detail piece would be less effective than its existing piece and that share would be flat to slightly declining.
Impact of Predictive Modeling
It's no coincidence that the performance of Product X improved consistently in the months following the introduction of the new piece, while Product Y saw market share go flat and decline during the same period of time. Given the size of these brands, it is estimated that the impact in sales as a result of these changes was +/- $10 to $30 million. Certainly, new prescriptions are driven by many factors, but correlation of pre-launch test results in the "lab" with actual results achieved by sales reps in the field is indicative of the power to predict performance.
The detail piece can be a powerful tool in the improvement of sales performance for pharma, as it represents the tangible intersection of marketing and sales execution. However, inconsistent detail-piece development has led to inconsistent use of the detail piece. But if the development of the detail piece is validated against actual prescribing, sales should be more likely to embrace it. Marketing, therefore, should track the effectiveness of a piece and update it when it is needed rather than on a pre-determined cycle. With predictive models now available, this should help to improve sales force effectiveness.
Reed Business Information launched Pharma Asia Magazine, a bi-monthly publication.
• Doremus, an Omnicom company, launched a communications-focused anthropological think tank called IN:SITE.
• DME, a division of Davids Productions, launched a newsletter for pharmacists, Current Concepts in Pharmacy Management. The company also launched a pharmacists Web site, ccpharm.com
Health Learning Systems,a division of CommonHealth, hired Aimee Roca as vice president of professional relations. The company also hired Jodi Andrews and Kim Gelnaw as program directors.
• Daniel Corey joined PharmaStrat as a recruiting analyst in the strategic services department. Brian Corvino joined the company as senior manager of strategic services. • The Zitter Group hired Ed W. Szostak as vice president of business development and Jack Lin as director of analytics product develpment and management.
Mike Luby is president and CEO of TargetRx, Inc. He can be reached at email@example.com
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape